Capricor Therapeutics Inc (NASDAQ:CAPR) Shares Acquired by Nuveen Asset Management LLC

Nuveen Asset Management LLC grew its holdings in Capricor Therapeutics Inc (NASDAQ:CAPR) by 392.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 169,111 shares of the biotechnology company’s stock after acquiring an additional 134,791 shares during the period. Nuveen Asset Management LLC owned about 0.37% of Capricor Therapeutics worth $2,334,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also recently made changes to their positions in the business. Farallon Capital Management LLC acquired a new position in Capricor Therapeutics during the fourth quarter valued at $31,056,000. Vanguard Group Inc. lifted its holdings in shares of Capricor Therapeutics by 44.4% in the 4th quarter. Vanguard Group Inc. now owns 2,276,784 shares of the biotechnology company’s stock valued at $31,420,000 after buying an additional 700,243 shares during the period. Altium Capital Management LLC grew its stake in shares of Capricor Therapeutics by 150.5% during the 4th quarter. Altium Capital Management LLC now owns 714,000 shares of the biotechnology company’s stock worth $9,853,000 after purchasing an additional 429,000 shares during the period. Black Diamond Financial LLC purchased a new position in Capricor Therapeutics in the fourth quarter valued at $3,833,000. Finally, Geode Capital Management LLC raised its holdings in Capricor Therapeutics by 37.8% in the 4th quarter. Geode Capital Management LLC now owns 879,468 shares of the biotechnology company’s stock worth $12,139,000 after purchasing an additional 241,279 shares during the period. Institutional investors and hedge funds own 21.68% of the company’s stock.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. HC Wainwright restated a “buy” rating and set a $77.00 price objective on shares of Capricor Therapeutics in a research report on Monday, March 17th. Roth Capital initiated coverage on Capricor Therapeutics in a report on Tuesday, May 20th. They issued a “buy” rating and a $31.00 price objective on the stock. Cantor Fitzgerald restated an “overweight” rating and set a $30.00 target price on shares of Capricor Therapeutics in a report on Wednesday, May 14th. Finally, Wall Street Zen lowered Capricor Therapeutics from a “hold” rating to a “sell” rating in a research report on Thursday, May 22nd. One analyst has rated the stock with a sell rating and six have assigned a buy rating to the company. According to data from MarketBeat, Capricor Therapeutics has a consensus rating of “Moderate Buy” and a consensus price target of $35.50.

Capricor Therapeutics Stock Up 3.2%

CAPR stock opened at $10.21 on Tuesday. The stock has a market cap of $466.36 million, a price-to-earnings ratio of -9.63 and a beta of 0.85. Capricor Therapeutics Inc has a 52-week low of $3.52 and a 52-week high of $23.40. The business has a fifty day moving average of $10.15 and a two-hundred day moving average of $13.05.

Capricor Therapeutics (NASDAQ:CAPR) last posted its quarterly earnings data on Tuesday, May 13th. The biotechnology company reported ($0.53) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.33) by ($0.20). Capricor Therapeutics had a negative net margin of 146.86% and a negative return on equity of 112.95%. The firm had revenue of $2.73 million during the quarter, compared to analysts’ expectations of $3.16 million. During the same quarter in the prior year, the firm posted ($0.31) EPS. As a group, sell-side analysts anticipate that Capricor Therapeutics Inc will post -1.21 EPS for the current year.

Capricor Therapeutics Profile

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.